非酒精性脂肪性肝病患者血清脂肪细胞因子研究进展*

doi:10.3969/j.issn.1672-5069.2014.03.034

实用肝脏病杂志 ›› 2014, Vol. 17 ›› Issue (3): 329-333.doi: 10.3969/j.issn.1672-5069.2014.03.034

非酒精性脂肪性肝病患者血清脂肪细胞因子研究进展^*

王萍综述, 李强审校

150086哈尔滨市哈尔滨医科大学附属第二临床医院内分泌代谢病科/糖尿病医院/哈尔滨医科大学激素与内分泌疾病重点实验室

收稿日期:2013-11-07 出版日期:2014-06-30 发布日期:2016-04-11
通讯作者: 李强,E-mail：15303609296 @126.com
作者简介:王萍,女,27岁,硕士研究生。主要从事糖尿病及非酒精性脂肪性肝病的诊断与治疗研究。E-mail：wangping060510@163.com
基金资助:
黑龙江省科技攻关项目（编号：GA07C303107）

Adipocytokines in nonalcoholic fatty liver diseases

Wang Ping, Li Qiang

Department of Endocrinology and Metabolism Diseases,Second Affiliated Hospital,Harbin Medical University,Harbin 150086

Received:2013-11-07 Online:2014-06-30 Published:2016-04-11

摘要/Abstract

摘要： 作为代谢综合征的肝脏表现,非酒精性脂肪性肝病（NAFLD）的主要特征为胰岛素抵抗（IR）和肝脂肪沉积。脂肪细胞因子作为脂肪细胞分泌的多肽,在NAFLD和IR的发病中发挥着重要的作用。本文综述了瘦素、脂联素、视黄醇结合蛋白4、成纤维细胞生长因子21和趋化素等新发现的细胞因子与NAFLD发病之间的关系。

关键词: 非酒精性脂肪性肝病, 脂肪细胞因子, 胰岛素抵抗

Abstract: Nonalcoholic fatty liver disease （NAFLD） is a part of hepatic manifestation of the metabolic syndrome. Its main features are fat deposition in liver and insulin resistance （IR）. Adipokines, a group of polypeptides secreted by adipocyte cells, play an important role in the pathogenesis of NAFLD and IR. In this paper,the focus is emphasized on the roles of adipokines in NAFLD,such as leptin, adiponectin, retinol binding protein 4,fibroblast growth factor 21,chemerin and other emerging factors.

Key words: Non-alcoholic fatty liver disease, Adipocytokines, Insulin resistance

王萍综述, 李强审校. 非酒精性脂肪性肝病患者血清脂肪细胞因子研究进展^*[J]. 实用肝脏病杂志, 2014, 17(3): 329-333.

Wang Ping, Li Qiang. Adipocytokines in nonalcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(3): 329-333.

参考文献

[1] Myers MG,Cowley MA,Munzberg H, et al. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol,2008,70:537-556.
[2] 潘莉,韩真.脂肪细胞因子在非酒精性脂肪肝发病机制中的作用. 实用肝脏病杂志,2010,13（2）：151-154.
[3] 王永兵,宋红杰,王悟云,等.海门地区体检人群脂肪肝检出及危险因素分析. 实用肝脏病杂志,2006,9（6）：343-344.
[4] Ravussin E,Smith SR,Mitchell JA,et al. Enhanced weight loss with pramlintide/metreleptin:an integrated neurohormonal approach to obesity pharmacotherapy. Obesity（Silver Spring）,2009,17（9）:1736-1743.
[5] Safar Zadeh E,Lungu AO,Cochran EK,et al. The liver diseases of lipodystrophy:the long-term effect of leptin treatment. J Hepatol,2013,59（1）:131-137.
[6] Imajo K,Fujita K,Yoneda M,et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell metab,2012,16（1）:44-54.
[7] Kwon DH,Kang W,Nam YS,et al. Dietary protein restriction induces steatohepatitis and alters leptin/signal transducers and activators of transcription 3 signaling in lactating rats. J Nutrit Biochem,2012,23（7）:791-799.
[8] Kadowaki T,Yamauchi T,Kubota N,et al. Adiponectin and adiponectin receptors in insulin resistance,diabetes,and the metabolic syndrome. Clin Invest,2006,116（7）:1784-1792.
[9] 宋新文,申保生,王宏伟.非酒精性脂肪性肝病患者血清脂联素和瘦素水平变化. 实用肝脏病杂志,2013,16（2）：141-143.
[10] 杨瑞雪,马向华,沈捷. 脂联素和过氧化物酶体增殖物激活受体mRNA的表达与代谢综合征.医学研究生学报,2011,24（6）：578-581.
[11] 丁虹,黄飚,陈锦,等.非酒精性脂肪性肝病患者血清脂联素的检测意义. 实用肝脏病杂志,2011,14（6）：469-470.
[12] Liew PL,Chen CL,Lee YC,et al. Hepatic tumor necrosis factor-α,leptin and adiponectin expression in morbid obese patients:Clinicopathological correlations. Obesity Res Clin Pract,2012,6（1）:55-62.
[13] Koot BG,van der Baan-Slootweg OH,Bohte AE,et al.Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children. Obesity,2013,21 （3）:583-590.
[14] Serrano A,Pavón FJ,Suarez J,et al. Adiponectin promoter activator NP-1 reduces body weight and hepatic steatosis in high-fat diet-fed animals. Physiol Endocrinol Metab,2012,302 （7）:817-830.
[15] 李丽,闵若谦,展玉涛,等.血清视黄醇结合蛋白4对非酒精性脂肪性肝炎的诊断价值. 实用肝脏病杂志,2011,14（5）：351-353.
[16] Tan Y,Sun LQ,Kamal MA,et al. Suppression of retinol- binding protein 4 with RNA oligonucleotide prevents high-fat diet-induced metabolic syndrome and non-alcoholic fatty liver disease in mice. Biochim Biophys Acta,2011,1811（12）:1045-1053.
[17] 刘滨菘,李强,王薇,等.视黄醇结合蛋白4 与非酒精性脂肪肝病的相关研究. 中华内分泌代谢杂志,2013,29（1）：58-61.
[18] Petta S,Tripodo C,Grimaudo S,et al. High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. Dig Liver Dis,2011,43（5）:404-410.
[19] Nobili V,Alkhouri N,Alisi A,et al. Retinol-binding protein 4: a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol,2009,7（5）:575-579.
[20] Woo YC,Xu A,Wang Y,et al. Fibroblast growth factor 21 as an emerging metabolic regulator:clinical perspectives. Clin Endocrinol （Oxf）,2013,78（4）:489-496.
[21] Coskun T, Bina HA,Schneider MA,et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology,2008,149（12）:6018-6027.
[22] Yang C,Lu W,Lin T,et al. Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress. BMC Gastroenterol,2013,86（9）:576-584.
[23] Li H,Dong K,Fang Q,et al. High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease:a 3-year prospective study in China. Hepatology,2013,58（3）:557-563.
[24] Shen J,Chan HL,Wong GL,et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hetapol,2012,58（6）:1363-1370.
[25] Li X,Fan X,Ren F,et al. Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently. Diab Res Clin Pract,2011,93（1）:10-16.
[26] Goralski KB,McCarthy TC,Hanniman EA,et al. Chemerin,a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem,2007,282（38）:28175-28188.
[27] Krautbauer S,Wanninger J,Eisinger K,et al. Chemerin is highly expressed in hepatocytes and is induced in non-alcoholic steatohepatitis liver. Exp Mol Pathol,2013,95（2）:199-205.
[28] Henrike S,Adeline D,Christine P,et al. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. Clin Endocrinol Metab,2010,95（6）:2892-2896.
[29] Docke S,Lock JF,Birkenfeld AL,et al. Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease. Eur J Endocrinol,2013,169（5）:547-557.
[30] Wanninger J,Bauer S,Eisinger K, et al. Adiponectin upregulates hepatocyte CMKLR1 which is reduced in human fatty liver. Mol Cell Endocrinol,2012,349（2）:248-254.

非酒精性脂肪性肝病患者血清脂肪细胞因子研究进展^*

Adipocytokines in nonalcoholic fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[2]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[3]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[4]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[5]	武丹, 马向鹰. 非酒精性脂肪性肝病肝硬化患者胰岛素抵抗水平与颈动脉硬化程度和左心室功能研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 876-879.
[6]	张胥磊, 杨庆余, 韩秋玉, 缪鋆鋆, 蔡仁诚, 马亦旻. 自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化*[J]. 实用肝脏病杂志, 2019, 22(5): 660-663.
[7]	张兰华, 邵琴, 夏振娟. 非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 522-525.
[8]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[9]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[10]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[11]	霍会芹,巩晓红,李正宏. 采用实时三维超声和斑点追踪技术评价非酒精性脂肪性肝病肝硬化患者右心功能^*[J]. 实用肝脏病杂志, 2019, 22(2): 244-247.
[12]	苏淑婷,钟燕（综述）,宓余强（审校）. 非酒精性脂肪性肝病分级分期管理研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 293-296.
[13]	谢晓（综述）,陆伦根（审校）. 无创诊断和评估非酒精性脂肪性肝炎研究进展^*[J]. 实用肝脏病杂志, 2019, 22(2): 301-306.
[14]	张枫, 阎妍. 非酒精性脂肪性肝病患者血清载脂蛋白B水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(1): 61-64.
[15]	宋娜, 刘晓燕, 刘畅, 山秀杰, 苏东峰, 李丽慧. 非酒精性脂肪性肝病合并2型糖尿病患者血浆促甲状腺激素水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(1): 65-68.